Skip to main content
. 2021 Sep 25;3(4):fcab221. doi: 10.1093/braincomms/fcab221

Table 1.

Clinical and molecular characterization of the study cohort

Patient ID AP4-HSP subunit Allele 1 Allele 2 CADD PHRED
score
ACMG classification a Sex Age SPRS 4-FMS AP-4-HSP core features ATG9A ratio
P/_01 AP4B1 c.1345A>T (p.Arg449Ter) (Nonsense) c.1160_1161delCA (p.Thr387ArgfsTer30) (Frameshift) 36/33 Pathogenic/pathogenic M 3 y 11 m 18 2 9/9 1.65
P/_02 AP4B1 c.530_531insA (p.Asn178GlufsTer20) (Frameshift) c.114-2A>C p.? (Splice site) 32/34 Pathogenic/pathogenic F 5 y 3 m 15 3 7/9 1.59
P/_03 AP4B1 c.1216C>T (p.Arg406Ter) (Nonsense) c.1328T>C (p.Leu443Pro) (Missense) 41/28.1 Pathogenic/uncertain significance F 4 y 11 m 35 4 8/9 1.44
P/_04 AP4B1 c.1216C>T (p.Arg406Ter) (Nonsense) c.1328T>C (p.Leu443Pro) (Missense) 41/28.1 Pathogenic/uncertain significance F 4 y 10 m 22 3 8/9 1.70
P/_05 AP4B1 c.114-2A>C p.? (Splice site) c.114-2A>C p.? (Splice site) 34/34 Pathogenic/pathogenic F 7 y 5 m 32 3 8/9 1.71
P/_06 AP4B1 c.617G>A (p.Arg206Gln) (Missense) c.617G>A (p.Arg206Gln) (Missense) 33/33 Likely pathogenic/likely pathogenic M 4 y 8 m 22 3 8/9 1.39
P/_07 AP4B1 c.1160_1161delCA (p.Thr387ArgfsTer30) (Frameshift) c.1160_1161delCA (p.Thr387ArgfsTer30) (Frameshift) 33/33 Pathogenic/pathogenic M 8 y 10 m 41 4 9/9 1.55
P/_08 AP4B1 c.664delC (p.Leu222CysfsTer31) (Frameshift) c.1177C>T (p.Arg393Ter) (Nonsense) 28.9/40 Pathogenic/pathogenic M 1 y 9 m NA 4 8/9 1.75
P/_09 AP4B1 c.1608_1609insCA (p.Lys537GlnfsTer18) (Frameshift) c.1608_1609insCA (p.Lys537GlnfsTer18) (Frameshift) 32/32 Pathogenic/pathogenic M 7 y 2 m 22 2 8/9 1.63
P/_10 AP4M1 c.916C>T (p.Arg306Ter) (Nonsense) c.916C>T (p.Arg306Ter) (Nonsense) 39/39 Pathogenic/pathogenic F 31 y 11m NA 4 8/9 1.36
P/_11 AP4M1 c.218dupA (p.Asn73LysfsTer43) (Frameshift) c.851A>C (p.Tyr284Ser) (Missense) 24.5/29.5 Pathogenic/Uncertain Significance M 9 y 1 m 41 4 9/9 1.50
P/_12 AP4M1 c.916C>T (p.Arg306Ter) (Nonsense) c.694dupG (p.Glu232GlyfsTer21) (Frameshift) 39/33 Pathogenic/pathogenic M 18 m 29 4 9/9 1.46
P/_13 AP4M1 c.1025 + 2dupT p.? (Splice site) c.205A>C (p.Thr69Pro) (Missense) 34/22.4 Uncertain significance/uncertain significance M 5 y 10 m 0 2 6/9 1.37
P/_14 AP4S1 c.138 + 3_138 + 6delAAGT p.? (Splice site) c.138 + 3_138 + 6delAAGT p.? (Splice site) 33/33 Pathogenic/pathogenic F 4 y 11 m NA 3 7/9 1.39
P/_15 AP4S1 c.294 + 1G>T p.? (Splice site) c.294 + 1G>T p.? (Splice site) 35/35 Pathogenic/pathogenic M 3 y 6 m 19 3 9/9 1.52
P/_16 AP4S1 c.289C>T (p.Arg97Ter) (Nonsense) c.289C>T (p.Arg97Ter) (Nonsense) 50/50 Pathogenic/pathogenic F 4 y 2 m 22 2 9/9 1.64
P/_17 AP4S1 c.49dupT (p.Ser17PhefsTer2) (Frameshift) c.49dupT (p.Ser17PhefsTer2) (Frameshift) 30/30 Pathogenic/pathogenic F 12 y 9 m NA 3 8/9 1.51
P/_18 AP4S1 c.49dupT (p.Ser17PhefsTer2) (Frameshift) c.238_239insG (p.Ile80SerfsTer3) (Frameshift) 30/33 Pathogenic/pathogenic F 17 y 1 m 24 3 8/9 1.56
PVUS/VUS_01 AP4B1 c.1024G>T (p.Asp342Tyr) (Missense) c.868C>T (p.Arg290Cys) (Missense) 28.6/25.5 Uncertain significance/uncertain significance F 3 y 0 m NA 4 3/9 1.16
PVUS/VUS_02 AP4B1 c.409A>G (p.Arg137Gly) (Missense) c.409A>G (p.Arg137Gly) (Missense) 24.4/24.4 Uncertain significance/uncertain significance F 41 y 3 m NA 2 1/8 1.27

F, female; M, male; m, months; NA, not available; SPRS, Spastic Paraplegia Rating Scale; y, years. Reference sequences: AP4B1: NM_001253852.3; AP4M1: NM_004722.4; AP4E1: NM_007347.5; AP4S1: NM_007077.4.

a

Classification of variants based on ACMG criteria using VarSome (Kopanos et al., 2019). CADD PHRED scores were computed using version 1.6 (https://cadd.gs.washington.edu/score).27